Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD

Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD
Insights from a community oncologist on myeloma bispecific antibodies | Ira Zackon, MD
Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD
Preventing Myeloma Relapse Using a Response Adaptive Dosing Approach | Erin Meermeier, PhD
Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD
Belamaf + VRd for Newly Diagnosed Transplant-Ineligible Myeloma Patients | Saad Usmani, MD
Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD
Monoclonal Gammopathy of Renal Significance: Hematologic Perspective | Heather Landau, MD
First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD
First U.S. CAR-T Trial for AL Amyloidosis Shows Promise | Heather Landau, MD
Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD
Real-Time Symptom Tracking for Myeloma Patients | James Berenson, MD
Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD
Long-Term Success with Talquetamab Combo Therapy | Hang Quach, MD
Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD
Dual Antibody Combo (Tec + Tal) Shows Hope for Hard-to-Treat Myeloma | Saad Usmani, MD
Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD
Talquetamab Outcomes in R/R Myeloma with Extramedullary Disease | Aimaz Afrough, MD
Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD
Nirogacestat Enhances BCMA Expression & Improves Blenrep Response? | Malin Hultcrantz, MD, PhD
Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD
Is Adjusting Dosing The Right Approach for Frail Myeloma Patients? | Charlotte Pawlyn, PhD
Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD
Maintenance Strategies Post-ASCT for High-Risk Newly Diagnosed Myeloma | Arvind Suresh, MD